Leading Pharma, LLC

Leading Pharma, LLC is a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

news image

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More

PHARMA TECH

SCINEURO PHARMACEUTICALS AND MABYLON AG TO COLLABORATE ON DEVELOPMENT OF NOVEL THERAPEUTICS FOR NEUROLOGICAL DISEASES

SciNeuro Pharmaceuticals | October 26, 2021

news image

SciNeuro Pharmaceuticals a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, MabSciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA bin...

Read More

NEW VETERINARY MEDICINES REGULATION

Pharmaceutical Microbiology | January 16, 2020

news image

A new Veterinary Medicines Regulation (Regulation (EU) 2019/6) has been introduced to modernise the existing rules on the authorisation and use of veterinary medicines in the European Union (EU). This becomes applicable on 28 January 2022. The regulation contains new measures for increasing the availability and safety of veterinary medicines and enhances EU action against antimicrobial resistance. The European Medicines Agency (EMA) is working closely with the European Commission and other EU pa...

Read More

PHARMA TECH

PATHAI ANNOUNCES STRATEGIC PARTNERSHIP WITH ROCHE TO ENABLE DEVELOPMENT AND DISTRIBUTION OF DIGITAL PATHOLOGY DIAGNOSTICS

Roche | October 15, 2021

news image

PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Roche, a global pioneer in pharmaceuticals and diagnostics, announced a strategic partnership to develop and distribute PathAI's AI-powered technology through Roche's uPath enterprise software, enabling broad access to digital pathology diagnostics to support clinical research and companion diagnostic (CDx) programs globally. AI-powered pathology has the potential to inform biomar...

Read More
news image

PHARMACY MARKET

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More
news image

PHARMA TECH

SCINEURO PHARMACEUTICALS AND MABYLON AG TO COLLABORATE ON DEVELOPMENT OF NOVEL THERAPEUTICS FOR NEUROLOGICAL DISEASES

SciNeuro Pharmaceuticals | October 26, 2021

SciNeuro Pharmaceuticals a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, MabSciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA bin...

Read More
news image

NEW VETERINARY MEDICINES REGULATION

Pharmaceutical Microbiology | January 16, 2020

A new Veterinary Medicines Regulation (Regulation (EU) 2019/6) has been introduced to modernise the existing rules on the authorisation and use of veterinary medicines in the European Union (EU). This becomes applicable on 28 January 2022. The regulation contains new measures for increasing the availability and safety of veterinary medicines and enhances EU action against antimicrobial resistance. The European Medicines Agency (EMA) is working closely with the European Commission and other EU pa...

Read More
news image

PHARMA TECH

PATHAI ANNOUNCES STRATEGIC PARTNERSHIP WITH ROCHE TO ENABLE DEVELOPMENT AND DISTRIBUTION OF DIGITAL PATHOLOGY DIAGNOSTICS

Roche | October 15, 2021

PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Roche, a global pioneer in pharmaceuticals and diagnostics, announced a strategic partnership to develop and distribute PathAI's AI-powered technology through Roche's uPath enterprise software, enabling broad access to digital pathology diagnostics to support clinical research and companion diagnostic (CDx) programs globally. AI-powered pathology has the potential to inform biomar...

Read More